Replaces Prod. #: BML-CA310
Facilitates agonist induced elevation of cytosolic calcium at low concentrations (10µM). Antagonizes calmodulin at higher concentrations. Antipsychotic and sedative dopamine antagonist. Potent and irreversible inhibitor of cAMP-gated cationic channels. Inhibits DNA repair. Cell permeable. Potent neurotoxin.
Product Details
| Formula: | C21H24F3N3S . 2HCl |
| |
| MW: | 407.5 . 73.0 |
| |
| CAS: | 440-17-5 |
| |
| MI: | 14: 9680 |
| |
| RTECS: | SP1750000 |
| |
| Purity: | ≥98% (UHPLC) |
| |
| Identity: | Identity determined by IR. |
| |
| Appearance: | White to off-white powder. |
| |
| Solubility: | Soluble in water (50mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light and moisture. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non small cell lung carcinoma cells to DNA double-strand break induced cell death: A.G. Polischouk, et al.; Mol. Cancer Ther.
6, 2303 (2007),
Abstract;
Trifluoperazine protects brain plasma membrane Ca(2+)-ATPase from oxidative damaging: P. Souza dos Santos, et al.; Exp. Brain Res.
177, 347 (2007),
Abstract;
Trifluoperazine stimulates ionizing radiation induced cell killing through inhibition of DNA repair: S. Gangopadhyay, et al.; Mutat. Res.
633, 117 (2007),
Abstract;
Inhibition of Nav1.7 and Nav1.4 sodium channels by trifluoperazine involves the local anesthetic receptor: P.L. Sheets, et al.; J. Neurophysiol.
96, 1848 (2006),
Abstract;
Inhibition of olfactory cyclic nucleotide-activated current by calmodulin antagonists: S.J. Kleene; Br. J. Pharmacol.
111, 469 (1994),
Abstract;
Trifluoperazine-induced conformational change in Ca(2+)-calmodulin: M. Vandonselaar, et al.; Nat. Struct. Biol.
1, 795 (1994),
Abstract;
Trifluoperazine binding to porcine brain calmodulin and skeletal muscle troponin C: J. Massom, et al.; Biochemistry
29, 671 (1990),
Abstract;
Influence of calmodulin antagonist (stelazine) on agonist-induced calcium mobilization and platelet activation: G.H. Rao; BBRC
148, 768 (1987),
Abstract;
New drug evaluations amiloride (Midamor, Merck, Sharp and Dohme): H.L. Macfie, et al.; Drug Intel. Clin. Pharm.
15, 94 (1981),
Abstract;
